A practical reference on gastric juice protein: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2025-11-01. Anything still debated is marked as such rather than presented as settled.
Common synonyms in catalogs include pentadecapeptide BPC 157, BPC157, and the full sequence name. A CAS registry number in the 137525-51-0 range is frequently listed, though the assignment should be verified against the supplier certificate of analysis. The name itself is not a pharmacopoeial designation, and there is no standardized international nonproprietary name. Distinguishing genuine material from related fragments generally requires mass spectrometry, since several truncated sequences share similar chromatographic behavior.
BPC-157 is a synthetic pentadecapeptide whose sequence is commonly given as Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. It is described in the literature as a fragment of a larger protein found in human gastric juice, referred to as body protection compound. The peptide was first characterized in the early 1990s by a research group in Zagreb, Croatia. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Physical descriptions in supplier documents and papers usually list the compound as a white to off-white powder. It dissolves readily in water and in common aqueous buffers, and solutions are often prepared fresh before an experiment. Molecular mass near 1419 daltons helps verify identity during mass spectrometry. The powder is somewhat hygroscopic, so moisture exposure can alter the measured mass of a sample. Purity is typically reported as a percentage from chromatographic analysis.
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence is GEPPPGKPADDAGLV. Its name derives from the phrase body protection compound, a term applied to a protein fraction originally detected in human gastric juice. The short peptide is not that full protein; it corresponds to a stable fragment of the larger molecule. Researchers frequently describe it as a pentadecapeptide because it contains exactly fifteen residues. Its neutral molecular mass is approximately 1419 daltons.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Assessed by visual inspection under ordinary laboratory lighting |
| Molecular mass | Approximately 1419 Da | Monoisotopic mass for the fifteen-residue sequence |
| Solubility class | Freely soluble in water | Stock solutions commonly prepared in water or aqueous buffer |
| Typical storage temperature | -20 °C or below, desiccated | Lyophilized powder; repeated freeze-thaw cycles are usually avoided |
| Common analytical method | Reversed-phase HPLC with UV detection | Frequently paired with mass spectrometry to confirm identity |
Several mechanisms have been proposed to explain the activity observed in animal models. The most frequently cited involve signaling through vascular endothelial growth factor receptor 2 and modulation of the nitric oxide system. Researchers have also described interactions with protective pathways in the gut lining. These proposed mechanisms appear in the literature as hypotheses supported by preclinical observations, not as confirmed pathways in humans. The precise way the peptide produces its reported effects, and whether those effects carry across species, remain areas of active and unresolved investigation.
BPC-157 is a synthetic pentadecapeptide, meaning it consists of fifteen amino acids joined in a single chain. Its sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, a fragment corresponding to part of a larger protein found in human gastric juice. The peptide was first described in the 1990s by researchers in Zagreb who were studying gastric protective factors. It is not a naturally circulating hormone; it is a laboratory-made fragment derived from a stomach protein. The name is an abbreviation of body protection compound, with the number referring to the fragment's position in the source protein.
Most published work on BPC-157 comes from animal experiments rather than controlled human trials. Rodent models have examined its effects on gastrointestinal lesions, tendon and ligament injury, and blood vessel formation. These studies are often small and originate from a limited number of research groups, which affects how broadly the findings can be generalized. No large randomized human trial has been reported in the peer-reviewed literature. Discussion of the compound therefore rests largely on preclinical data, and questions about its effects in people remain open rather than settled.
Outside laboratory supply channels, the peptide is sold as a research chemical, a category that carries no requirement to demonstrate purity, identity, or freedom from contamination. Because it is not an approved medicine, products labeled BPC-157 sit in a regulatory gap in many countries, and actual content may differ from the label. Sports organizations list it among prohibited substances, so its presence in an athlete's sample can produce a doping finding regardless of how the material was obtained.
BPC-157 is a synthetic peptide of fifteen amino acids, written as GEPPPGKPADDAGLV, whose sequence matches part of a larger protein identified in human gastric juice. That parent protein was described in stomach-secretion research, and the fifteen-residue fragment was named body protection compound, which gives the peptide its common label. Material used in experiments is produced by solid-phase peptide synthesis rather than extracted from tissue. The reported molecular weight is about 1419 daltons, and the chain contains several proline residues, a feature that appears in discussions of its resistance to enzymatic breakdown.
Most published findings come from rodent models, where the peptide has been examined in wound-healing, gastrointestinal-lesion, tendon, and vascular-injury preparations. A smaller number of early human studies have been reported, chiefly in inflammatory bowel conditions, but the public record is short and has not led to marketing approval in the United States or the European Union. Reviewers therefore classify the compound as investigational, and whether animal results carry over to people remains an open question rather than a settled one.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most published work on BPC-157 consists of preclinical studies, including rodent models of tissue injury, gastrointestinal lesions, and vascular or tendon damage, together with in vitro cell assays. Reviews frequently note that the mechanisms proposed in these papers remain incompletely characterised and that findings have not been confirmed in large randomised human trials. The compound is widely sold as a research chemical rather than a licensed medicine, and labels commonly carry a statement that it is not for human use. Whether any of the reported animal effects translate to humans is an open question rather than an established result.
Interest in the peptide has grown through online communities that discuss self-administered use, which sits outside formal research settings. Regulatory status varies by country, and in many jurisdictions the compound is not approved as a therapeutic product. Questions about optimal routes of administration, long-term effects, and dose-response relationships remain open. Published pharmacokinetic data in humans are limited, and much of what circulates in popular discussion is extrapolated from animal work rather than measured directly in people.
BPC-157 is a synthetic peptide built from fifteen amino acids, referred to in the literature as a pentadecapeptide. Its sequence was derived from a larger protein found in human gastric juice, commonly called body protection compound. Researchers first described the fragment in the early 1990s and named it after the parent protein plus a numeric identifier. The peptide does not correspond to a single marketed medicine; it is primarily a laboratory research material. Suppliers distribute it as a lyophilized powder intended for experimental use.
Published work on BPC-157 spans several decades and covers a wide range of experimental models. Much of the early literature reports outcomes in animal studies involving induced injury to the gastrointestinal tract, tendons, and other tissues. The volume of preclinical reports is large, while controlled human trials remain scarce. This imbalance is a recurring point of discussion, because animal findings do not automatically translate into human effects. Reviews often note that study designs differ substantially across laboratories.
Anastrozole, sold under the brand name Arimidex among others, is an antiestrogenic medication used in addition to other treatments for breast cancer. Specifically it is used for hormone receptor-positive breast cancer. It has also been used to prevent breast cancer in those at high risk. It is taken orally. Common side effects of anastrozole include hot flashes, altered mood, joint pain, and nausea. Severe side effects include an increased risk of heart disease and osteoporosis. Use during pregnancy may harm the fetus. Anastrozole is in the aromatase-inhibiting family of medications. It works by blocking the production of estrogens in the body, and hence has antiestrogenic effects. Anastrozole was patented in 1987 and was approved for medical use in 1995. It is on the World Health Organization's List of Essential Medicines. Anastrozole is available as a generic medication. In 2023, it was the 194th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
== Discovery of PTD-DBM == Professor Kang-Yell Choi and his research team at Yonsei University in South Korea discovered a protein responsible for hair loss in the condition known as androgenetic alopecia. The responsible protein is called CXXC-type zinc finger protein 5 (CXXC5), which acts as a negative regulator for the Wnt/β-catenin pathway, involved in hair regeneration and wound healing. CXXC5 negatively regulates hair growth, and the researchers developed a new substance that promotes hair regeneration by controlling the function of CXXC5. When CXXC5 binds with the Dvl protein, which functions at the upstream of Wnt/β-catenin pathway, it suppresses hair regrowth and hair follicle neogenesis. The observation of CXXC5 overexpression in the bald scalp by Professor Choi’s team led to the development of PTD-DBM, which interferes with the CXXC5-Dvl protein-protein interaction (PPI). By topical application, PTD-DBM enhances hair regrowth as well as neogenesis. The hair growth promoting effect of PTD-DBM is further enhanced when used in combination with a Wnt/β-catenin signaling activator such as VPA, which is generally used as a drug for bipolar disorder and activates the Wnt/β-catenin pathway by inhibition of GSK3β. Currently, topical application of PTD-DBM or its combination with VPA has been used for treatment of hair loss.
In the late 1990s, some investigators thought that the fact that symptoms emerged when antidepressants were discontinued might mean that antidepressants were causing addiction, and some used the term "withdrawal syndrome" to describe the symptoms. While people taking antidepressants do not commonly exhibit drug-seeking behavior, stopping antidepressants leads to similar symptoms as found in drug withdrawal from benzodiazepines, and other psychotropic drugs. As such, some researchers advocate the term withdrawal over discontinuation, to communicate the similar physiological dependence and negative outcomes. Due to pressure from pharmaceutical companies who make antidepressants, the term "withdrawal syndrome" is no longer used by drug makers, and thus, most doctors, due to concerns that they may be compared to other drugs more commonly associated with withdrawal.
== Structure and membership == Article 10.(b) of the Draft Constitutional Declaration defines the Sovereignty Council to consist of five civilians chosen by the FFC, five military chosen by the TMC, and a civilian "selected by agreement" between the FFC and TMC. Under Article 10.(c) of the Draft Constitutional Declaration, for the first 21 months of the 39-month transitional period defined by the document, the chair of the Sovereignty Council was to be chosen by the five military members of the council. For the following 18 months, the chair was to be chosen by the five civilian members selected by the FFC. The military membership of the Sovereignty Council included General Abdel Fattah al-Burhan, General Hemedti, Lieutenant-General Yasser al-Atta, General Shams al-Din Khabbashi and Major-General Ibrahim Jabir Karim. Hemedti has been the deputy chairman of the Sovereignty Council in the past. The five civilians chosen by the FFC are Aisha Musa el-Said of the National Gathering Initiative; Siddiq Tawer, a prominent member of the Arab Socialist Ba'ath Party – Region of Sudan (and thereby a member of the National Consensus Forces) from the Nuba Mountains in South Kordofan; Mohamed al-Faki Suleiman of the Unionist Gathering from Northern Sudan; Hassan Sheikh Idris (or Hassan Mohamed Idris), a prominent member of the National Umma Party (and thereby a member of Sudan Call) from Kassala; and Mohammed Hassan Osman al-Ta'ishi of the Sudanese Professionals Association.
== Early life == Elizabeth Wettlaufer was born and raised in Zorra Township, a rural community near Woodstock, Ontario. Growing up in a staunchly Baptist household, she went on to earn a bachelor's degree in religious education counseling from London Baptist Bible College after graduating from Huron Park Secondary School in the mid-1980s. Wettlaufer then studied nursing at Conestoga College.
Sources: en.wikipedia.org
For secure communications, the PLA uses the Zhongxing and Fenghuo series of satellites which enable secure data and voice transmission over C-band, Ku-band, and UHF. PLA deployment of anti-satellite and counterspace satellites including those of the Shijian and Shiyan series have also brought significant concern from western nations. The PLA also plays a significant role in the Chinese space program. To date, all the participants have been selected from members of the PLA Air Force. China became the third country in the world to have sent a man into space by its own means with the flight of Yang Liwei aboard the Shenzhou 5 spacecraft on 15 October 2003, the flight of Fei Junlong and Nie Haisheng aboard Shenzhou 6 on 12 October 2005, and Zhai Zhigang, Liu Boming, and Jing Haipeng aboard Shenzhou 7 on 25 September 2008. The PLA started the development of an anti-ballistic and anti-satellite system in the 1960s, code named Project 640, including ground-based lasers and anti-satellite missiles. On 11 January 2007, China conducted a successful test of an anti-satellite missile, with an SC-19 class KKV. The PLA has tested two types of hypersonic space vehicles, the Shenglong Spaceplane and a new one built by Chengdu Aircraft Corporation. Only a few pictures have appeared since it was revealed in late 2007. Earlier, images of the High-enthalpy Shock Waves Laboratory wind tunnel of the CAS Key Laboratory of high-temperature gas dynamics (LHD) were published in the Chinese media. Tests with speeds up to Mach 20 were reached around 2001.
=== 1950s === In 1953, the company became a public company via an initial public offering on the New York Stock Exchange. In 1954, the company acquired Davison Chemical Company and Dewey & Almy Chemical Company, entering the specialty chemicals and specialty materials industries and establishing the basis for the current product lines. In 1955, the company elected a chairman of the company who was not a member of the Grace family, which was a first in the 101-year history of company. The company appointed Charles E. Wilson, who was the former CEO of General Electric. His predecessor for his position was William Grace Holloway.
As of 2019, there were an estimated 72,000 centenarians living in the U.S.; the 2020 census officially counted 80,139, and the 2010 census had 53,364. However, the U.S. Census Bureau claimed in 1999 that as many as a third of people stating their age as over 100 might be exaggerating. In the United States, centenarians may request a letter of congratulation from the president of the United States to mark their longevity. Strom Thurmond became the first sitting Senator to reach 100 on 5 December 2002. Jimmy Carter became the first former president to reach the age of 100 on 1 October 2024. Today also presents a segment honoring centenarians and older, sponsored by Smuckers. The tradition was created in 1983 by weather presenter Willard Scott, and is now presented by his successor Al Roker. In the state of New Mexico, centenarians have been exempt from state income tax since tax year 2002, if they are not dependents of another taxpayer.
Louisville hotspot (23) 53°36′S 140°36′W, w= 1 az= 316° ±5° rate= 67 ±5 mm/yr Possibly related to the Ontong Java Plateau (125–120 Ma). Foundation hotspot/Ngatemato seamounts (57) 37°42′S 111°06′W, w= 1 az= 292° ±3° rate= 80 ±6 mm/yr Macdonald hotspot (24) 29°00′S 140°18′W, w= 1 az= 289° ±6° rate= 105 ±10 mm/yr North Austral/President Thiers (President Thiers Bank, 58) 25°36′S 143°18′W, w= (1.0) az= 293° ± 3° rate= 75 ±15 mm/yr Arago hotspot (Arago Seamount, 59) 23°24′S 150°42′W, w= 1 az= 296° ±4° rate= 120 ±20 mm/yr Maria/Southern Cook hotspot (Îles Maria, 60) 20°12′S 153°48′W, w= 0.8 az= 300° ±4° Samoa hotspot (35) 14°30′S 168°12′W, w= 0.8 az= 285°±5° rate= 95 ±20 mm/yr Crough hotspot (Crough Seamount, 61) 26°54′S 114°36′W, w= 0.8 az= 284° ± 2° Pitcairn hotspot (31) 25°24′S 129°18′W, w= 1 az= 293° ±3° rate= 90 ±15 mm/yr Society/Tahiti hotspot (38) 18°12′S 148°24′W, w= 0.8 az= 295°±5° rate= 109 ±10 mm/yr Marquesas hotspot (26) 10°30′S 139°00′W, w= 0.5 az= 319° ±8° rate= 93 ±7 mm/yr Caroline hotspot (4) 4°48′N 164°24′E, w= 1 az= 289° ±4° rate= 135 ±20 mm/yr Hawaii hotspot (12) 19°00′N 155°12′W, w= 1 az= 304° ±3° rate= 92 ±3 mm/yr Socorro/Revillagigedos hotspot (37) 19°00′N 111°00′W Guadalupe hotspot (11) 27°42′N 114°30′W, w= 0.8 az= 292° ±5° rate= 80 ±10 mm/yr Cobb hotspot (5) 46°00′N 130°06′W, w= 1 az= 321° ±5° rate= 43 ±3 mm/yr Bowie/Pratt-Welker hotspot (3) 53°00′N 134°48′W, w= 0.8 az= 306° ±4° rate= 40 ±20 mm/yr
=== Africa === In northern Africa, B. burgdorferi sensu lato has been identified in Morocco, Algeria, Egypt and Tunisia. Lyme disease in sub-Saharan Africa is presently unknown, but evidence indicates it may occur in humans in this region. The abundance of hosts and tick vectors would favor the establishment of Lyme infection in Africa. In East Africa, two cases of Lyme disease have been reported in Kenya. According The Federation of Infectious Diseases Societies of Southern Africa, Lyme disease is not known to be endemic in either South Africa or Mozambique.
Sources: en.wikipedia.org
It is a synthetic peptide built from fifteen amino acids, with a mass of roughly 1419 daltons. The sequence is reported to match a fragment of a protein present in human gastric juice. It is not a naturally circulating hormone.
It is normally supplied as a lyophilized powder in a sealed vial. The powder dissolves readily in water, and stock solutions are typically prepared shortly before use. Cold storage is standard laboratory practice.
The letters are generally read as shorthand for body protection compound. That label comes from the original research context rather than from formal nomenclature. No standardized nonproprietary name exists for the peptide.
The letters BPC stand for body protection compound. The number 157 refers to a specific fragment designation from early work on gastric proteins. The full name is a label for a synthetic fifteen-amino-acid peptide rather than a naturally isolated drug.